Article
ESR1-Activating Mutations Confer Metabolic Vulnerabilities in ER+ Breast Cancer.
Cancer research - 2 Feb 2026
Bonechi Francesca, Bacci Marina, Lorito Nicla, Smiriglia Alfredo, Subbiani Angela, Pagliantini Edoardo, Comito Giuseppina, Gangarossa Giulia, Duatti Assia, El Botty Rania, Sourd Laura, Romano Elisabetta, Tani Gabriele, Segatto Ilenia, Belletti Barbara, Meattini Icro, Livi Lorenzo, Cerbelli Bruna, Botticelli Andrea, Fiorillo Marco, Marangoni Elisabetta, Morandi Andrea
Abstract excerpt
Endocrine therapy (ET) is the standard of care for estrogen receptor (ER)-positive breast cancer. Point mutations in the ligand-binding domain of the gene encoding the estrogen receptor (ESR1) are rare in naïve ER+ breast cancer while becoming common in the ET-resistant setting. In this study, we found that ESR1 mutations expose breast cancers to critical vulnerabilities related to lipid metabolism. Particularly,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.